NIOX GroupCSSPF 77 EBIT per Share is $0.04 as of Dec. 2025. GuruFocus rates CSSPF with a GF Score™ of 77/100 and a GF Value™ of $1.21 (Significantly Undervalued). The stock has 1 warning sign investors should review. Among 690 Medical Devices & Instruments companies, NIOX Group ranks better than 96.96% on this metric.
NIOX Group's EBIT per Share for the
six
months ended in Dec. 2025 was $0.02.
Its EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.04.
During the past 12 months, the average EBIT per Share Growth Rate of NIOX Group was 47.10% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 84.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for NIOX Group's EBIT per Share or its related term are showing as below:
CSSPF'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -49 Med: 1.6 Max: 84.2
Current: 84.2
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of NIOX Group was 84.20% per year. The lowest was -49.00% per year. And the median was 1.60% per year.
CSSPF's 3-Year EBIT Growth Rate is ranked better than 96.96% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.65
vs CSSPF: 84.20
NIOX Group's EBIT for the
six
months ended in Dec. 2025 was $6.96 Mil.
NIOX Group (OTCPK:CSSPF) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
NIOX Group EBIT per Share Related Terms
NIOX Group EBIT per Share Historical Data
* Premium members only.
The historical data trend for NIOX Group's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $0.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NIOX Group (CSSPF) has a EBIT per Share of $0.04 as of Dec. 2025. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on NIOX Group and its competitors. According to the industry distribution chart, NIOX Group ranks #21 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 3%.
Is NIOX Group's EBIT per Share too high?
NIOX Group's current EBIT per Share is $0.04. The Medical Devices & Instruments industry median EBIT per Share is 9.65. NIOX Group's value of $0.04 is 99.6% below this industry median. Based on the distribution chart, NIOX Group ranks #21 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, NIOX Group has a GF Score™ of 77/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does NIOX Group's EBIT per Share compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, NIOX Group ranks #21 out of 690 companies for EBIT per Share. This places NIOX Group in the top 3% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.65. NIOX Group's value of $0.04 is 99.6% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.65, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NIOX Group's current EBIT per Share of $0.04 is 99.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on NIOX Group and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.65 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NIOX Group's current EBIT per Share is $0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NIOX Group stock overvalued right now?
Based on GuruFocus' analysis, NIOX Group (CSSPF) is currently considered Significantly Undervalued. The stock's GF Value™ is $1.21, compared to a current price of $0.75 — trading 38% below its estimated fair value. The current EBIT per Share is $0.04 and 99.6% below the Medical Devices & Instruments industry median of 9.65. NIOX Group's overall GF Score™ is 77/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For NIOX Group (CSSPF), the current EBIT per Share is $0.04 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NIOX Group (CSSPF) Overvalued in 2026?
Based on GuruFocus' analysis, NIOX Group stock appears to be undervalued.
The current stock price of $0.75 is trading 38% below its estimated GF Value™ of $1.21.
GuruFocus considers NIOX Group to be Significantly Undervalued.
Key valuation signals for CSSPF:
EBIT per Share: $0.04
GF Value™: $1.21 vs. price of $0.75 (38% below fair value)
Industry Position: 99.6% below the Medical Devices & Instruments median (#21 of 690)
No single metric tells the full story. See the CSSPF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NIOX Group PLC is engaged in improving the diagnosis, monitoring and management of both asthma and COPD by providing greater patient access to FeNO testing. The company is engaged in the design, development, and commercialization of medical devices for the measurement of FeNO, a precise biomarker for type 2 inflammation which is present in asthma and COPD. Its device, NIOX VERO, is increasingly recognised by healthcare professionals as an important tool to improve the diagnosis, monitoring and management of asthma and COPD. It operates in single segment of NIOX relates to the portfolio of products used to improve asthma diagnosis, monitoring and management by measuring fractional exhaled nitric oxide (FeNO).
77GF Score
Get the complete analysis for CSSPF
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CSSPF has been successfully added to your 
